Lexaria Bioscience Corp. (LEXX) — SEC Form D Filing

Lexaria Bioscience Corp. (LEXX) filed an SEC Form D on September 21, 2026, reporting $113K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 21, 2026
Amount reported
$113K
Round stage
Growth stage, as indicated by the company's established revenue of over five million dollars and a small, opportunistic capital raise of one hundred thirteen thousand dollars.
Industry
Biotechnology
Website
https://www.lexariabioscience.com

What the company does

Revenue: $5,000,001 - $25,000,000. Exemption: Rule 506(b). Incorporated: NEVADA

Problem

Poor bioavailability and slow absorption of lipophilic active pharmaceutical ingredients limit the clinical efficacy and consumer appeal of oral medications and supplements.

Solution

Lexaria Bioscience Corp. (LEXX) develops and licenses its patented DehydraTECH drug delivery technology to improve the speed of onset, bioavailability, and brain penetration of active molecules.

Why now

The surging demand for alternative, non-invasive delivery methods for GLP-1 agonists and cannabinoids requires immediate innovation in oral bioavailability.

Source: SEC EDGAR Form D filing